CJC-1295 + DAC

CJC-1295 + DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) to extend circulating half-life in research models. This modified peptide is investigated in laboratory and controlled clinical settings for its ability to bind GHRH receptors and stimulate endogenous growth hormone (GH) secretion through physiologic signaling pathways. The DAC component enables prolonged receptor interaction and sustained pharmacokinetic exposure compared with shorter-acting GHRH analogs, making it distinct in endocrine research frameworks.

In vitro systems and animal models evaluate endpoints including pulsatile GH secretion dynamics, insulin-like growth factor-1 (IGF-1) response patterns, receptor binding affinity, and downstream signaling cascades associated with somatotropic axis regulation. Controlled clinical investigations have assessed pharmacokinetics, serum GH and IGF-1 concentrations, and safety markers under structured dosing conditions.